[SPONSORED REPORTS] Huons gains approval from FDA for 4th straight year

The photo shows the Lidocaine Hydrochloride Injection USP, 1 percent, 50 milligrams/ 5 milliliters (10 milligrams/ milliliter) ampule which received FDA approval. [HUONS]

Huons is actively expanding its presence in the global market.

The Korean health care company has received approval from the Food and Drug Administration (FDA) 4 years in a row for its injectable products which enabled easy access to the U.S. market.

On May 8, the company succeeded in gaining approval for Lidocaine Hydrochloride Injection USP, 1 percent, 50 milligrams/ 5 milliliters (10 milligrams/ milliliter) which is a vial-standard product of the 1 percent Lidocaine injection 5 milliliter ampoule. The company has already obtained approval for 3 other ampoule injections in the past, but this is the first time it has received a license regarding vial-standard products from the FDA. Through this approval, it is expected the company will obtain more permits for various vial-type injectable products produced in the future.

Approval from the FDA shows that Huons has become a leader in the injectable industry and its products’ quality have reached a global standard.
There are two significant driving factors behind the success of the health care company.

Firstly, Huons built a huge factory in Jecheon, North Chungcheong, which became a vanguard for exporting injectable products to the U.S. market. From the regular inspection conducted by the FDA last year, the factory met strict standards in terms of the quality of its products and received good marks for its production process and the overall facilities.

Also, Huons has carefully planned a road map to enter the U.S. market and made an agreement with its partnership company which enables a steady long-term supply of its product. The products which received FDA approval were all in high demand making it easier for the company to consolidate its position in the market.

Huons also exported anesthesia and sedative injections such as Ketamine Hydrochloride, Dobutamine Hydrochloride and Midazolam to countries like Luxembourg which desperately need medicinal products to deal with the coronavirus.

Ketamine Hydrochloride is an anesthesia that is used in varying degrees of surgery. It is usually used as a supplementary therapy with other anesthesia. Dobutamine Hydrochloride, a cardiac stimulant, is known to increase the cardiac output of the patients whose heart rate has been weakened due to surgery. It can be also administered to coronavirus patients with serious symptoms. Midazolam is a kind of benzodiazepine hypnotic sedative which lessens anxiety and helps patients sleep. This sedative is used to calm coronavirus patients who are relying on ventilators.

Huons has exported Ketamine Hydrochloride and Dobutamine Hydrochloride to Luxembourg which requested an emergency supply of the medical products. The company also plans to export to other countries in Europe and South America.

“Due to the outbreak of the coronavirus, we are seeing an increase in demand of products such as sedatives and injections,” said Um Key-an, CEO of Huons. “Since the world is facing an unprecedented risk, we will do our utmost to provide injections to help countries deal with the virus.

BY PARK JI-HOON [park.jihoon@joongang.co.kr]